PriceTargets.com logo

NYSEAMERICAN:ARMP - Armata Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.33
  • Forecasted Upside: 31.42 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.58 As of 03/3/2021 01:00 AM ET
▼ -0.09 (-1.59%)
1 month | 3 months | 12 months
Get New Armata Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARMP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.33
▲ +31.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Armata Pharmaceuticals in the last 3 months. The average price target is $7.33, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 31.42% upside from the last price of $5.58.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Armata Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
8/14/2020Maxim GroupReiterated RatingBuy$8.00
i
Rating by Jason McCarthy at Maxim Group
6/22/2020LADENBURG THALM/SH SHReiterated RatingBuy$9.00
i
6/18/2020Maxim GroupReiterated RatingBuy$8.00
i
Rating by Jason McCarthy at Maxim Group
5/16/2020Maxim GroupInitiated CoverageBuy$8.00
i
Rating by Jason McCarthy at Maxim Group
5/15/2020HC WainwrightReiterated RatingBuy$9.00 ➝ $5.00
i
Rating by Joseph Pantginis at HC Wainwright
3/20/2020HC WainwrightReiterated RatingBuy$9.50 ➝ $9.00
i
Rating by Joseph Pantginis at HC Wainwright
3/19/2020Maxim GroupReiterated RatingBuy$8.00
i
Rating by Jason McCarthy at Maxim Group
3/13/2020Brookline Capital ManagementReiterated RatingBuy
i
Rating by K. Raja at Brookline Capital Management
2/6/2020Maxim GroupInitiated CoverageBuy$8.00
i
1/29/2020HC WainwrightReiterated RatingBuy$9.50
i
Rating by Joseph Pantginis at HC Wainwright
11/13/2019HC WainwrightReiterated RatingBuy$9.50
i
Rating by Joseph Pantginis at HC Wainwright
10/31/2019HC WainwrightReiterated RatingBuy$7.00 ➝ $9.50
i
Rating by Joseph Pantginis at HC Wainwright
8/21/2019LADENBURG THALM/SH SHReiterated RatingBuy$9.00
i
8/15/2019HC WainwrightReiterated RatingBuy$7.00
i
Rating by Joseph Pantginis at HC Wainwright
7/15/2019LADENBURG THALM/SH SHReiterated RatingBuy$9.00
i
6/19/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$9.00
i
5/23/2019HC WainwrightSet Price TargetBuy$7.00
i
Rating by Joseph Pantginis at HC Wainwright
(Data available from 3/4/2016 forward)
Armata Pharmaceuticals logo
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.
Read More

Today's Range

Now: $5.58
$5.51
$5.66

50 Day Range

MA: $2.87
$2.65
$3.12

52 Week Range

Now: $5.58
$2.52
$10.48

Volume

16,165 shs

Average Volume

65,736 shs

Market Capitalization

$114.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Armata Pharmaceuticals?

The following equities research analysts have issued research reports on Armata Pharmaceuticals in the last year: Brookline Capital Management, HC Wainwright, LADENBURG THALM/SH SH, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for ARMP.

What is the current price target for Armata Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Armata Pharmaceuticals in the last year. Their average twelve-month price target is $7.33, suggesting a possible upside of 31.4%. LADENBURG THALM/SH SH has the highest price target set, predicting ARMP will reach $9.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Armata Pharmaceuticals in the next year.
View the latest price targets for ARMP.

What is the current consensus analyst rating for Armata Pharmaceuticals?

Armata Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARMP will outperform the market and that investors should add to their positions of Armata Pharmaceuticals.
View the latest ratings for ARMP.

What other companies compete with Armata Pharmaceuticals?

Other companies that are similar to Armata Pharmaceuticals include Opthea, AVROBIO, Cellular Biomedicine Group, Freeline Therapeutics, Cardiff Oncology, Codiak BioSciences, Innate Pharma, SQZ Biotechnologies, Aptose Biosciences, Outlook Therapeutics, Innate Pharma, Surface Oncology, Lineage Cell Therapeutics, Autolus Therapeutics and Eiger BioPharmaceuticals.

How do I contact Armata Pharmaceuticals' investor relations team?

Armata Pharmaceuticals' physical mailing address is 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292. The company's listed phone number is (310) 655-2928 and its investor relations email address is [email protected] The official website for Armata Pharmaceuticals is www.armatapharma.com.